Treatment of Epiretinal Membranes With Ranibizumab (LERM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01238393
Recruitment Status : Completed
First Posted : November 10, 2010
Last Update Posted : January 13, 2016
Information provided by (Responsible Party):
Queen's University

Brief Summary:
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Condition or disease Intervention/treatment Phase
Epiretinal Membrane Drug: intravitreal ranibizumab Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study
Study Start Date : November 2010
Actual Primary Completion Date : November 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Ranibizumab
('intravitreal ranibizumab' )
Drug: intravitreal ranibizumab
monthly injections x3 +/- 2nd series of 3
Other Name: Lucentis

Primary Outcome Measures :
  1. Evidence of improvement measured by optical coherence tomography [ Time Frame: 3 and 6 months ]

Secondary Outcome Measures :
  1. Distance visual acuity (ETDRS) [ Time Frame: 3 and 6 months ]
  2. Near visual acuity (Snellen) [ Time Frame: 3 and 6 months ]
  3. Subjective change in symptoms [ Time Frame: 3 and 6 months ]
  4. Amsler grid improvement [ Time Frame: 3 and 6 months ]
  5. Quality of life improvement [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • symptomatic idiopathic epiretinal membrane

Exclusion Criteria:

  • vision worse than 6/18 and fit for surgery
  • prior vitreoretinal surgery or injection
  • diabetes
  • any past or current form of retinal vein occlusion or neovascularization
  • age-related macular degeneration
  • other condition causing significant limitation of visual potential

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01238393

Canada, Ontario
Queen's University, Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Principal Investigator: Jeffrey Gale, MD Queen's University

Responsible Party: Queen's University Identifier: NCT01238393     History of Changes
Other Study ID Numbers: OPTH-092-10
First Posted: November 10, 2010    Key Record Dates
Last Update Posted: January 13, 2016
Last Verified: January 2016

Additional relevant MeSH terms:
Epiretinal Membrane
Retinal Diseases
Eye Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents